Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 3
1975 1
1976 4
1979 2
1980 1
1981 3
1982 1
1991 2
1998 1
2003 2
2004 6
2005 5
2006 6
2007 5
2008 4
2009 10
2010 11
2011 11
2012 12
2013 12
2014 10
2015 8
2016 13
2017 13
2018 31
2019 30
2020 35
2021 13
Text availability
Article attribute
Article type
Publication date

Search Results

216 results
Results by year
Filters applied: . Clear all
Page 1
Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD).
Good P, Haywood A, Gogna G, Martin J, Yates P, Greer R, Hardy J. Good P, et al. BMC Palliat Care. 2019 Dec 6;18(1):110. doi: 10.1186/s12904-019-0494-6. BMC Palliat Care. 2019. PMID: 31810437 Free PMC article. Clinical Trial.
There is increasing interest in the use of medicinal cannabinoids, but there is little high quality evidence to guide clinicians. This study aims to define the role of cannabidiol (CBD) in the management of symptom burden in patients with advanced cancer undergoing standar …
There is increasing interest in the use of medicinal cannabinoids, but there is little high quality evidence to guide clinicians. This study …
Effect of Cannabidiol and delta9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Arkell TR, et al. JAMA. 2020 Dec 1;324(21):2177-2186. doi: 10.1001/jama.2020.21218. JAMA. 2020. PMID: 33258890 Free PMC article. Clinical Trial.
IMPORTANCE: Cannabis use has been associated with increased crash risk, but the effect of cannabidiol (CBD) on driving is unclear. OBJECTIVE: To determine the driving impairment caused by vaporized cannabis containing delta9-tetrahydrocannabinol (THC) and CBD. ...
IMPORTANCE: Cannabis use has been associated with increased crash risk, but the effect of cannabidiol (CBD) on driving is unclear. OB …
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Devinsky O, et al. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. N Engl J Med. 2017. PMID: 28538134 Free article. Clinical Trial.
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred more frequently in the cannabidiol group than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and ab …
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred …
An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia.
van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. van de Donk T, et al. Pain. 2019 Apr;160(4):860-869. doi: 10.1097/j.pain.0000000000001464. Pain. 2019. PMID: 30585986 Free PMC article. Clinical Trial.
We tested 4 different cannabis varieties with exact knowledge on their [INCREMENT]-tetrahydrocannabinol (THC) and cannabidiol (CBD) content: Bedrocan (22.4-mg THC, <1-mg CBD; Bedrocan International BV, Veendam, the Netherlands), Bediol (13.4-mg THC, 17.8-mg CBD; Bedroca …
We tested 4 different cannabis varieties with exact knowledge on their [INCREMENT]-tetrahydrocannabinol (THC) and cannabidiol (CBD) c …
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Devinsky O, et al. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. N Engl J Med. 2018. PMID: 29768152 Free article. Clinical Trial.
RESULTS: A total of 225 patients were enrolled; 76 patients were assigned to the 20-mg cannabidiol group, 73 to the 10-mg cannabidiol group, and 76 to the placebo group. ...The median percent reduction from baseline in drop-seizure frequency during the treatment per …
RESULTS: A total of 225 patients were enrolled; 76 patients were assigned to the 20-mg cannabidiol group, 73 to the 10-mg cannabid
The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities.
Xu DH, Cullen BD, Tang M, Fang Y. Xu DH, et al. Curr Pharm Biotechnol. 2020;21(5):390-402. doi: 10.2174/1389201020666191202111534. Curr Pharm Biotechnol. 2020. PMID: 31793418 Clinical Trial.
There has, however, been an increasing body of evidence for the use of cannabinoids in the treatment of chronic, noncancer pain. The efficacy of a topically delivered cannabidiol (CBD) oil in the management of neuropathic pain was examined in this four-week, randomized and …
There has, however, been an increasing body of evidence for the use of cannabinoids in the treatment of chronic, noncancer pain. The efficac …
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR. Devinsky O, et al. Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24. Lancet Neurol. 2016. PMID: 26724101 Clinical Trial.
The primary objective was to establish the safety and tolerability of cannabidiol and the primary efficacy endpoint was median percentage change in the mean monthly frequency of motor seizures at 12 weeks. ...The median reduction in monthly motor seizures was 36.5% (IQR 0- …
The primary objective was to establish the safety and tolerability of cannabidiol and the primary efficacy endpoint was median percen …
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group. Thiele EA, et al. Lancet. 2018 Mar 17;391(10125):1085-1096. doi: 10.1016/S0140-6736(18)30136-3. Epub 2018 Jan 26. Lancet. 2018. PMID: 29395273 Clinical Trial.
We therefore assessed the efficacy and safety of cannabidiol as an add-on anticonvulsant therapy in this population of patients. ...One patient (1%) died in the cannabidiol group, but this was considered unrelated to treatment. INTERPRETATION: Add-on cannabidiol
We therefore assessed the efficacy and safety of cannabidiol as an add-on anticonvulsant therapy in this population of patients. ...O …
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group. Devinsky O, et al. Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14. Neurology. 2018. PMID: 29540584 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. METHODS: Patients aged 4-10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice dai …
OBJECTIVE: To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in c …
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Leweke FM, et al. Transl Psychiatry. 2012 Mar 20;2(3):e94. doi: 10.1038/tp.2012.15. Transl Psychiatry. 2012. PMID: 22832859 Free PMC article. Clinical Trial.
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. ...Either treatment was safe and led to significant clinical improvement, but cannabidiol displayed a mar
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the
216 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page